|Day Low/High||16.99 / 17.62|
|52 Wk Low/High||15.92 / 44.49|
Studies Advance the Knowledge of Vectra DA Utility for Clinicians and Patients with RA
Expands Its Companion Diagnostic Collaboration with AstraZeneca
New Data Will Be Presented at the NEI Psychopharmacology Congress
Data Being Presented at ASDP Demonstrate a Diagnostic Accuracy of >95 Percent
Employees Will Facilitate Classroom Learning and Inspire Students to Pursue Careers in Science
Those who thought we were ready to break down look foolish again.
Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.
New Data Support the Utility of the Company's Advanced Companion Diagnostic Tests
Former Insurance Industry Executive Brings Significant Pharmaceutical, Diagnostic and Managed Markets Experience
Three Studies to Be Featured at the NSGC 35th Annual Education Conference
Here's a technical look at how to trade five stocks that are within range of triggering big breakout trades.
The most recent short interest data was recently released for the 07/29/2016 settlement date, and Myriad Genetics, Inc. is one of the most shorted stocks of the Russell 3000, based on 21.79 "days to cover" versus the median component at 6.42.
AIR, DO, MLNX, HALL and MYGN were all recently downgraded by TheStreet's Quant Ratings.
Jefferies lowered its price target to $20 on Myriad Genetics (MYGN) stock this morning saying that 'hereditary cancer cracks are emerging.'